MYNZ
Mainz Biomed BV
NASDAQ: MYNZ · HEALTHCARE · DIAGNOSTICS & RESEARCH
$0.41
-3.73% today
Updated 2026-05-01
Market cap
$7.90M
P/E ratio
—
P/S ratio
16.01x
EPS (TTM)
$-5.28
Dividend yield
—
52W range
$1 – $5
Volume
0.8M
Mainz Biomed BV (MYNZ) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | $281393.00 | $493565.00 | $577348.00 | $529877.00 | $895479.00 | $893991.00 |
| Revenue growth (YoY) | — | +75.4% | +17.0% | -8.2% | +69.0% | -0.2% |
| Cost of revenue | $342664.00 | $370480.00 | $399726.00 | $347726.00 | $385820.00 | $319108.00 |
| Gross profit | $-61271.00 | $123085.00 | $177622.00 | $182151.00 | $509659.00 | $574883.00 |
| Gross margin | -21.8% | 24.9% | 30.8% | 34.4% | 56.9% | 64.3% |
| R&D | $250316.00 | $311851.00 | $466689.00 | $3.66M | $9.59M | $5.84M |
| SG&A | $388785.00 | $347994.00 | $8.45M | $17.83M | $13.42M | $8.08M |
| Operating income | $-921909.00 | $-766090.00 | $-9.72M | $-26.44M | $-26.64M | $-18.70M |
| Operating margin | -327.6% | -155.2% | -1684.4% | -4990.6% | -2975.5% | -2091.2% |
| EBITDA | $-702077.00 | $-257641.00 | $-11.28M | $-25.72M | $-25.01M | $-19.56M |
| EBITDA margin | -249.5% | -52.2% | -1953.9% | -4853.6% | -2793.1% | -2187.8% |
| EBIT | $-755119.00 | $-410478.00 | $-11.35M | $-26.18M | $-26.05M | $-20.58M |
| Interest expense | $201936.00 | $268792.00 | $339171.00 | $289324.00 | $809581.00 | $1.08M |
| Income tax | $217711.00 | $299282.00 | $377122.00 | $65389.00 | $1.92M | — |
| Effective tax rate | -29.4% | -104.1% | -3.3% | -0.2% | -7.9% | 0.0% |
| Net income | $-957055.00 | $-586895.00 | $-11.69M | $-26.45M | $-26.30M | $-21.65M |
| Net income growth (YoY) | — | +38.7% | -1891.9% | -126.3% | +0.6% | +17.7% |
| Profit margin | -340.1% | -118.9% | -2024.8% | -4992.2% | -2936.5% | -2421.8% |